Abstract 5749
Background
Neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of age.
Methods
We collected clinical data from 13 Italian NENs dedicated Units. Patients with WD NENs, in progression on previous treatments, included SSA, and subsequently treated with HDD-SSA, were considered.
Results
170 pts were included: 61.76% male, 38.24% female. The median age at the diagnosis was 58.83. Regarding the site of origin, the most frequent was gastro-intestinal system (54.71%), followed by pancreas (27.06%) and lung (8.24%). G1 NENs were 54.11%, G2 42.94% and typical lung carcinoid 2.95%; 31.76% were affected by a carcinoid syndrome or clinical conditions such as gastrinoma, insulinoma and Zollinger-Ellison. The median PFS was 20.18 months. Side effects (SEs) were registered in 25 pts (14.71%), the most frequent were cholecystitis (4%), G1 asthenia (12%), G1 hyperglycemia (8%), G1 steatorrhea (76%). We divided patients in 4 groups considering the age at the diagnosis: lower than 60 years, 61-70, 71-80 and more than 81 years. With the increase of age there was a higher percentage of SEs (Tab.1) with a maximum percentage of 20.41% in the group with an age of 71-80 years. The treatment was well tolerated without life-threatening side effects also in the group of patients with an age > 70 years. Tab. 1Table: 520P
Age at the diagnosis (years) | % side effects |
---|---|
<60 | 10,00% |
61-70 | 13,73% |
71-80 | 20,41% |
>81 | 20,00% |
Conclusions
We concluded that in this setting of patients, with an age >70 and a WD NEN in progression to standard doses of SSA, HD-SSA represents a safe and effective second line therapy with a median PFS of 20.80 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract
3425 - Feasibility and impact of prospective DPYD screening in the Irish population
Presenter: Mohammed Zameer
Session: Poster Display session 2
Resources:
Abstract
1972 - Diet-derived metabolites and the risk of colorectal cancer: a nested case-control study in a population-based cohort, the Singapore Chinese Health Study
Presenter: Dawn Chong
Session: Poster Display session 2
Resources:
Abstract
4103 - Loss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy
Presenter: Erin Stella Sullivan
Session: Poster Display session 2
Resources:
Abstract
4309 - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.
Presenter: Bozena Cybulska-Stopa
Session: Poster Display session 2
Resources:
Abstract
3554 - Patient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)
Presenter: Pia Österlund
Session: Poster Display session 2
Resources:
Abstract
4572 - Discovery and Diagnosis of Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results from a European Survey
Presenter: Iga Rawicka
Session: Poster Display session 2
Resources:
Abstract
4783 - Adherence to recommended intake of calcium and colorectal cancer risk in the HEXA study
Presenter: Jeeyoo Lee
Session: Poster Display session 2
Resources:
Abstract
5106 - Body size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study
Presenter: Christina Siesing
Session: Poster Display session 2
Resources:
Abstract
3364 - Middle East & North Africa Registry to characterize RAS mutation status and tumor specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)
Presenter: Mohamed Oukkal
Session: Poster Display session 2
Resources:
Abstract